Lilly Delivers Strong Third-Quart...(l sales compared with 25 percent of ...),Health

total sales in the third quarter of 2006.

-- Net income and earnings per share both grew 6 percent to $926.3 million

and $.85, respectively, compared with third-quarter 2006 net income of

$873.6 million and earnings per share of $.80. Reported results

include a $.06 per share charge for a reduction in expected product

liability insurance recoveries.

Third-Quarter Highlights - Pro Forma Adjusted Results

-- Sales increased 13 percent, to $4.587 billion.

-- Sales of products launched this decade grew 30 percent and represented

33 percent of total sales.

-- Net income and earnings per share grew 20 percent and 18 percent, to

$996.4 million and $.91, respectively.

Product Sales Highlights

------------------------

% Change % Change

(Dollars in Third Quarter Over/(Under) Year-to-Date Over/(Under)

millions) 2007 2006 2006 2007 2006 2006

---- ---- ---- ---- ---- -----------

Zyprexa(R) $1,166.1 $1,084.7 8% $3,487.1 $3,207.1 9%

Cymbalta 513.2 348.6 47% 1,474.6 892.3 65%

Gemzar(R) 394.4 354.6 11% 1,166.9 1036.9 13%

Humalog(R) 362.5 322.2 12% 1,060.4 947.3 12%

Evista(R) 263.2 257.9 2% 805.0 775.0 4%

Cialis (1) 311.4 55.0 N/M 797.6 161.2 N/M

Humulin(R) 243.3 230.0 6% 711.9 668.3 7%

Alimta 215.0 157.2 37% 610.0 440.4 39%

Forteo 180.5 149.1 21% 511.1 422.2 21%

Strattera 130.5 126.4 3% 412.6 422.7 (2)%

Total Sales
'/>"/>